CF Foundation President & CEO Talks with Lead Investigator of
VX-770 Clinical Trials
October 24, 2008
Among the exciting updates announced at the CF Foundation’s 22nd annual North American Cystic Fibrosis Conference this week in Orlando, Fla., is news of the most recent Phase 2a study of Vertex Pharmaceuticals, Inc.’s compound VX-770, which aims to treat the basic defect in CF.
Robert J. Beall, Ph.D., president and CEO of the Foundation, joined Frank Accurso, M.D., director of the CF care center at the Children’s Hospital in Denver, Colo. and principal investigator of VX-770’s clinical trials, to discuss the exciting news.
Watch here to learn more about VX-770.